Houston families received massive aid thanks to Catholic Charities. Family Houston/Facebook

The global pandemic has wreaked havoc on families in need. But in a much-needed bright spot, a local organization has initiated help to those hardest hit by the COVID downturn.

Catholic Charities of the Archdiocese of Galveston-Houston announced that more than 51,000 families have received aid from the $61.4 million from the Harris County COVID-19 Emergency Direct Assistance Program.

Need-based funds came courtesy of the county's CARES funding and provided a one-time, $1,200 payment to 51,167 eligible applicants, per a press release.
Money was distributed nearly equally across Harris County's four precincts (except for the Precinct 2 surplus), including Houston residents inside Harris County.

To ensure fairness, families were selected from the application pool using a random statistical model that ensured no discrimination, according to Catholic Charities. Funds could be used for any type of emergency expense (housing, food, utilities, healthcare, childcare, transportation, etc.), and families could apply without cooperation from a landlord.

Breaking down the numbers provided in a press release, Harris County initially designated $40 million for the fund; another $20 million was allocated in November. An additional $1.4 million was allocated to the Direct Assistance fund and was earmarked directly for Precinct 2 recipients due to a shortfall of participants in the County's Small Business Grant Program, bringing the program's total to $61.4 million.

Even non-citizen residents who were unable to obtain CARES money due to federal grant requirements will be helped thanks to private funds; those monies are currently being distributed, according to the charity.

Meanwhile, the program provided jobs to nearly 250 laid-off residents, injecting $2.2. million into the local economy.

"Catholic Charities is honored and grateful that Harris County selected our team to serve the community in this way," said Catholic Charities' president and CEO Cynthia N. Colbert, in a statement. "This task was in line with our faith-based mission, which compels us to ensure that every client is treated with respect and dignity."

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”